FDA clears investigational drug for ALS gene therapy trials
The neurobiology of food attraction
22 April 2021Globally, no increase seen in suicides in early COVID-19 pandemic
22 April 2021FDA clears investigational drug for ALS gene therapy trials
Apic Bio, a gene therapy company developing treatment options for patients with rare genetic diseases and co-founded by UMass Medical School’s Robert H. Brown Jr., DPhil, MD, announced that the FDA has cleared its investigational new drug (IND) application for APB-102, a gene therapy candidate designed to treat a common cause of familial amyotrophic lateral sclerosis.
